Harvard Bioscience, Inc. Acquires CMA Microdialysis' Preclinical Business

Harvard Bioscience, Inc. HBIO today announced that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets. CMA Microdialysis AB is a privately held Swedish manufacturer of microdialysis products. Founded in 1984, the company pioneered the microdialysis technique for in vivo sampling and monitoring of organs and tissues. This acquisition is complementary to the current Harvard Apparatus research products for neuroscience applications. Chane Graziano, CEO of Harvard Bioscience, commented, "The acquisition of CMA Microdialysis' preclinical business provides Harvard with a leading technology to add to our line of specialized tools for biological research. The business unit will remain in Sweden under the leadership of Erik Düring. We expect this acquisition to be immediately accretive to earnings."